Journal
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
Volume 17, Issue 8, Pages 712-718Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jamda.2016.03.020
Keywords
Body composition; sarcopenic obesity; chronic obstructive pulmonary disease; 6-minute walking distance; fibrinogen; systemic inflammation
Categories
Funding
- American Board of Internal Medicine
- Advantage Healthcare
- Almirall
- American Thoracic Society
- AstraZeneca
- Baxter
- Boehringer Ingelheim
- Chiesi
- ClearView Healthcare
- Cleveland Clinic
- Complete Medical Group
- CSL
- Dailchi Sankyo
- Decision Resources
- Forest
- Gerson Lehman
- Grifols
- GroupH
- Guidepoint Global
- Haymarket
- Huron Consulting
- Inthought
- Johnson and Johnson
- Methodist Health System-Dallas
- NCI Consulting
- Novartis
- Pearl
- Penn Technology
- Pfizer
- Merck
- GlaxoSmithKline [SCO10490, NCT00292552]
- Nycomed
- ECLIPSE
- Takeda
- European Respiratory Society [STRTF 2013-2399]
- Planning-Shop
- PSL FirstWord
- Qwessential
- WebMD
Ask authors/readers for more resources
Background: Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcopenic obesity (SO). Objective: To explore the effects of SO on exercise capacity, health status, and systemic inflammation in COPD. Design/Settings/Participants: Baseline data collected from a total of 2548 participants (2000 patients with COPD, mean age (SD), 63.5 (7.1) years; and 548 controls, 54.8 (9.0) years) from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, a multicenter longitudinal observational study, were used. Measurements: All participants were divided into 4 body composition phenotypes using bioelectrical impedance analysis: (1) normal body composition, (2) obesity, (3) sarcopenia, and (4) SO. In patients with COPD, the 6-minute walking distance, disease-specific health status, and plasma inflammatory markers were compared among the respective body composition groups. Results: Patients with COPD were 3 times more likely to present with SO compared with controls without COPD (odds ratio [OR] 3.3, 95% confidence interval [CI] 2.0-5.4, P <.001). In patients with COPD, SO was related to reduced 6-minute walking distance (-28.0 m, 95% CI -45.6 to -10.4), P <.01) and to higher systemic inflammatory burden (an elevation of at least 2 inflammatory markers, OR 1.6, 95% CI 1.1-2.5, P =.028) compared with the normal body composition group after adjustments for age, sex, smoking, body mass index, and airflow limitation. Conclusions: Our findings suggest that SO is associated with worse physical performance and higher systemic inflammatory burden compared with other body composition phenotypes in patients with COPD. (C) 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available